At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Abiraterone Acetate +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Abiraterone Acetate, Laboratory Biomarker Analysis, and 2 other interventions for Hormone-Resistant Prostate Cancer and 3 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartDec 2012
Primary CompletionMar 2020
TodayJul 2026
First PostedJan 2, 2012
Enrollment StartDec 1, 2012
Primary CompletionMar 12, 2020
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 14.5 years ago
Interventions
Abiraterone Acetatedrug
Given by mouth
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies
Prednisonedrug
Given PO